Financial Tearsheet
Company Overview
Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.
Recent Financial News
IR Contacts
| Investor Relations | Transfer Agent |
|
Cindy Rizzo, CORE IR |
AST Financial, Bryan Anderson,
|
| Auditors | Corporate Counsel |
|
Grant Thornton LLP |
Charles Vaughn,
|
Stock Performance
| Stock Fundamentals | Value |
|---|---|
| Today's Open | 4.62 |
| Volume | 171 |
| Day Range | 4.62 - 4.62 |
| 52 Week Range | 3.82 - 12.25 |
| Bid/Ask | 4.51 / 4.68 |
| Bid/Ask Size | 100 X 100 |
| Previous Close | 4.59 |
| Market Cap | 23.09 million |
| Shares Outstanding | 5.03 million |
| Dividend/Yield | 0.00 / 0.00% |
| EPS (TTM) | -1.840000 |
| P/E Ratio (TTM) | N/A |
